Adjuvant Aromatase Inhibitors for Early Breast Cancer After Chemotherapy-Induced Amenorrhoea: Caution and Suggested Guidelines

Key Points

• To evaluate the safety and clinical implications of administering adjuvant aromatase inhibitors in women with chemotherapy-induced amenorrhea and provide clinical guidance.
• Assessed endocrine therapy selection and the risks of ovarian function recovery during aromatase inhibitor therapy after chemotherapy-induced amenorrhea.
• Evaluated biochemical monitoring requirements, focusing on the necessity of high-sensitivity immunoassays to detect residual or recovering ovarian activity.
• Aromatase inhibitor administration can promote unexpected recovery of ovarian function in women experiencing chemotherapy-induced amenorrhea.
• Accurate detection of ovarian reactivation requires highly sensitive immunoassays to prevent inappropriate endocrine therapy and optimize clinical management.